ログイン
ランキング
お知らせ
ログイン
文献詳細
増大特集 神経疾患の診断における落とし穴—誤診を避けるために
文献概要
多発ニューロパチーの診断では，神経伝導検査所見が決め手となることがある。しかし，慢性炎症性脱髄性多発ニューロパチー（CIDP）の電気診断においては，いくつかのピットフォールがある。POEMS症候群，アミロイドーシス，抗MAG抗体ニューロパチーはCIDPと初期に診断されることがあるが，いずれの疾患もそれぞれに適した治療戦略がある。神経伝導検査所見を適切に解釈するには，注意深い診察と的確な鑑別診断の想起が重要である。
参考文献
1)Créange A, Careyron A: The diagnosis of chronic inflammatory demyelinating polyneuropathy: a Delphi-method approach. J Neurol 260: 3015-3022, 2013
2)Neligan A, Reilly MM, Lunn MP: CIDP: mimics and chameleons. Pract Neurol 14: 399-408, 2014
3)Van den Bergh PY, Hadden RD, Bouche P, Cornblath DR, Hahn A, et al: European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--First Revision. J Peripher Nerv Syst 15: 1-9, 2010
4)Kuwabara S, Isose S, Mori M, Mitsuma S, Sawai S, et al: Different electrophysiological profiles and treatment response in ‘typical’ and ‘atypical’ chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 86: 1054-1059, 2015
5)Ikeda S, Koike H, Nishi R, Kawagashira Y, Iijima M, et al: Clinicopathological characteristics of subtypes of chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 90: 988-996, 2019
6)Nasu S, Misawa S, Sekiguchi Y, Shibuya K, Kanai K, et al: Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 83: 476-479, 2012
7)Hadden RD, Nobile-Orazio E, Sommer CL, Hahn AF, Illa I, et al: European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first revision. J Peripher Nerv Syst 15: 185-195, 2010
8)Koike H, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, et al: Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid 18: 53-62, 2011
9)Svahn J, Petiot P, Antoine JC, Vial C, Delmont E, et al: Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features. J Neurol Neurosurg Psychiatry 89: 499-505, 2018
10)Lehmann HC, Burke D, Kuwabara S: Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry 90: 981-987, 2019
11)Querol L, Rojas-Garcia R, Diaz-Manera J, Barcena J, Pardo J, et al: Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm 2: e149, 2015［doi: 10.1212/NXI.0000000000000149］
12)Sekijima Y, Ueda M, Koike H, Misawa S, Ishii T, et al: Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis 13: 6, 2018［doi: 10.1186/s13023-017-0726-x］
13)Manganelli F, Pisciotta C, Reilly MM, Tozza S, Schenone A, et al: Nerve conduction velocity in CMT1A: what else can we tell? Eur J Neurol 23: 1566-1571, 2016
14)Koike H, Tanaka F, Hashimoto R, Tomita M, Kawagashira Y, et al: Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry 83: 152-158, 2012
15)Bunschoten C, Blomkwist-Markens PH, Horemans A, van Doorn PA, Jacobs BC: Clinical factors, diagnostic delay, and residual deficits in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripheral Nervous Syst: 24: 253-259, 2019
16)Allen JA, Lewis RA: CIDP diagnostic pitfalls and perception of treatment benefit. Neurology 85: 498-504, 2015
17)Devaux JJ, Miura Y, Fukami Y, Inoue T, Manso C, et al: Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 86: 800-807, 2016
18)Miura Y, Devaux JJ, Fukami Y, Manso C, BelghaziM, et al: Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain 138: 1484-1491, 2015
19)Suichi T, Misawa S, Beppu M, Takahashi S, Sekiguchi Y, et al: Prevalence, clinical profiles, and prognosis of POEMS syndrome in Japanese nationwide survey. Neurology 93: e975-e983, 2019［doi: 10.1212/WNL.0000000000008062］
20)Gertz MA: Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment. Am J Hematol 93: 1169-1180, 2018
21)Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, et al: Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79: 785-792, 2012
22)Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, et al: Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379: 11-21, 2018
23)Dalakas MC: Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies. Ther Adv Neurol Disord 11: 1756285617746640, 2018［doi: 10.1177/1756285617746640］
掲載誌情報
